Mostrar el registro sencillo del ítem
dc.contributor.author
Beaty III, Orren
dc.contributor.author
Berg, Stacey
dc.contributor.author
Blaney, Susan
dc.contributor.author
Malogolowkin, Marcio
dc.contributor.author
Krailo, Mark
dc.contributor.author
Knight, Ronald
dc.contributor.author
Schaiquevich, Paula Susana
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Stewart, Clinton
dc.contributor.author
Chen, Zhengjia
dc.contributor.author
Nelson, Marvin
dc.contributor.author
Voss, Stephan
dc.contributor.author
Ivy, S. Percy
dc.contributor.author
Adamson, Peter C.
dc.date.available
2023-03-14T13:19:36Z
dc.date.issued
2010-09
dc.identifier.citation
Beaty III, Orren; Berg, Stacey; Blaney, Susan; Malogolowkin, Marcio; Krailo, Mark; et al.; A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study; Wiley-liss, div John Wiley & Sons Inc.; Pediatric Blood & Cancer; 55; 3; 9-2010; 440-445
dc.identifier.issn
1545-5009
dc.identifier.uri
http://hdl.handle.net/11336/190460
dc.description.abstract
Background. Platinating agents are used in the treatment of a spectrum of childhood cancers. Oxaliplatin, a third generation platinum compound, may provide less toxicity and be more effective. A phase 2 study was performed to estimate the response rate to single agent oxaliplatin in patients with refractory pediatric solid tumors, and to further describe the toxicities and pharmacokinetics of the drug in this population. Patients and Methods. Subjects, ≤21 years of age at original diagnosis, received oxaliplatin (130 mg/m 2) intravenously every 21 days. Prior platinum exposure was acceptable. Histologies included: Ewing sarcoma/peripheral PNET, osteosarcoma, rhabdomyosarcoma, neuroblastoma, high and low grade astrocytoma, brain stem glioma, ependymoma, hepatoblastoma and selected rare tumors. A two-stage design, enrolling 10+10 subjects, was used for each disease stratum. Limited sampling pharmacokinetic studies were performed. Results. Of 124 eligible subjects (75 males), 113 were evaluable for response and 69 (62%) had received platinum previously. Only one objective response was observed, a partial response in a 6-year-old child with ependymoma. An additional 13 subjects with various other solid tumors had stable disease, receiving a median (range) of 13.5 (2-17) cycles. Five subjects completed 17 treatment cycles. Thrombocytopenia was the most common toxicity observed. The median (range) terminal half-life and clearance for ultrafiltrable platinum were 293 (187-662 hr) and 14.0 (1.9-24.9 L/hr/m2), respectively (n=49). Conclusions. Although reasonably well tolerated, oxaliplatin administered as a single agent has limited activity in pediatric patients with relapsed or refractory solid tumors.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Wiley-liss, div John Wiley & Sons Inc.
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
OXALIPLATIN
dc.subject
PEDIATRIC
dc.subject
PHARMACOKINETICS
dc.subject
PHASE II STUDY
dc.subject
REFRACTORY SOLID TUMOR
dc.subject.classification
Oncología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-03-12T15:44:05Z
dc.journal.volume
55
dc.journal.number
3
dc.journal.pagination
440-445
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Nueva Jersey
dc.description.fil
Fil: Beaty III, Orren. Mission Hospital; Estados Unidos
dc.description.fil
Fil: Berg, Stacey. Texas Children's Cancer Center And Hematology Service; Estados Unidos
dc.description.fil
Fil: Blaney, Susan. Texas Children's Cancer Center And Hematology Service; Estados Unidos
dc.description.fil
Fil: Malogolowkin, Marcio. Children's Hospital Los Angeles; Estados Unidos
dc.description.fil
Fil: Krailo, Mark. Children's Oncology Group; Estados Unidos
dc.description.fil
Fil: Knight, Ronald. Sanofi Aventis; Estados Unidos
dc.description.fil
Fil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. St. Jude Children's Research Hospital; Estados Unidos
dc.description.fil
Fil: Stewart, Clinton. St. Jude Children's Research Hospital; Estados Unidos
dc.description.fil
Fil: Chen, Zhengjia. Children's Oncology Group; Estados Unidos
dc.description.fil
Fil: Nelson, Marvin. Children's Hospital Los Angeles; Estados Unidos
dc.description.fil
Fil: Voss, Stephan. Dana Farber Cancer Institute and Children's Hospital Boston; Estados Unidos
dc.description.fil
Fil: Ivy, S. Percy. National Cancer Institute; Estados Unidos
dc.description.fil
Fil: Adamson, Peter C.. Children's Hospital of Philadelphia; Estados Unidos
dc.journal.title
Pediatric Blood & Cancer
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/pbc.22544
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/pbc.22544
Archivos asociados